PURPOSE: The aim of this study was to investigate the expression of the PRL-3 in human invasive breast cancer and to evaluate its clinical and prognostic significance. Its potential role in the invasive-metastatic properties of invasive breast cancer was also investigated. METHODS: Protein expression of PRL-3 was evaluated by immunohistochemistry for a consecutive series of 82 invasive human breast cancer tissues and 63 matched lymph node metastases, including PRL-3 mRNA expression analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) in malignant, nonmalignant breast tissue samples and lymph node metastases. We investigated the correlation of PRL-3 with clinicopathologic features, Overall and recurrence-free survival distribution curves were assessed using the Kaplan-Meier test and log-rank statistics, followed by Cox proportional hazards regression model. RESULTS: We found that 70.7% patients expressed a high level of PRL-3 protein in their tumors, and its over expression was positive correlated with lymph node metastasis (LNM) (P = 0.011). Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002). Univariate analysis showed that the positive expression of PRL-3 was a poor risk prognostic factor (OS, P = 0.045; RFS, P = 0.034). Multivariate analysis using the Cox regression model indicated that high PRL-3 expression was an independent unfavorable prognostic factor for RFS. CONCLUSIONS: These results strongly suggest that PRL-3 expression can indicate the potential role of LNM to some extent. Increasing the risk of tumor metastasis (OR = 3.889). Our results also imply that PRL-3 might be a novel molecular marker for predicting relapse of invasive breast cancer.
PURPOSE: The aim of this study was to investigate the expression of the PRL-3 in humaninvasive breast cancer and to evaluate its clinical and prognostic significance. Its potential role in the invasive-metastatic properties of invasive breast cancer was also investigated. METHODS: Protein expression of PRL-3 was evaluated by immunohistochemistry for a consecutive series of 82 invasive humanbreast cancer tissues and 63 matched lymph node metastases, including PRL-3 mRNA expression analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) in malignant, nonmalignant breast tissue samples and lymph node metastases. We investigated the correlation of PRL-3 with clinicopathologic features, Overall and recurrence-free survival distribution curves were assessed using the Kaplan-Meier test and log-rank statistics, followed by Cox proportional hazards regression model. RESULTS: We found that 70.7% patients expressed a high level of PRL-3 protein in their tumors, and its over expression was positive correlated with lymph node metastasis (LNM) (P = 0.011). Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002). Univariate analysis showed that the positive expression of PRL-3 was a poor risk prognostic factor (OS, P = 0.045; RFS, P = 0.034). Multivariate analysis using the Cox regression model indicated that high PRL-3 expression was an independent unfavorable prognostic factor for RFS. CONCLUSIONS: These results strongly suggest that PRL-3 expression can indicate the potential role of LNM to some extent. Increasing the risk of tumor metastasis (OR = 3.889). Our results also imply that PRL-3 might be a novel molecular marker for predicting relapse of invasive breast cancer.
Authors: W F Matter; T Estridge; C Zhang; R Belagaje; L Stancato; J Dixon; B Johnson; L Bloem; T Pickard; M Donaghue; S Acton; R Jeyaseelan; V Kadambi; C J Vlahos Journal: Biochem Biophys Res Commun Date: 2001-05-25 Impact factor: 3.575
Authors: U A Miskad; S Semba; H Kato; Y Matsukawa; Y Kodama; E Mizuuchi; N Maeda; K Yanagihara; H Yokozaki Journal: Virchows Arch Date: 2007-01-18 Impact factor: 4.064
Authors: Petra den Hollander; Kathryn Rawls; Anna Tsimelzon; Jonathan Shepherd; Abhijit Mazumdar; Jamal Hill; Suzanne A W Fuqua; Jenny C Chang; C Kent Osborne; Susan G Hilsenbeck; Gordon B Mills; Powel H Brown Journal: Cancer Res Date: 2016-02-26 Impact factor: 12.701
Authors: Carmen M Dumaual; George E Sandusky; Han Weng Soo; Sean R Werner; Pamela L Crowell; Stephen K Randall Journal: Am J Transl Res Date: 2012-01-05 Impact factor: 4.060
Authors: N Nakayama; K Yamashita; T Tanaka; H Kawamata; A Ooki; T Sato; T Nakamura; M Watanabe Journal: Clin Exp Metastasis Date: 2015-11-12 Impact factor: 5.150
Authors: Kelley E McQueeney; Joseph M Salamoun; Jennifer G Ahn; Paula Pekic; Isabella K Blanco; Heather L Struckman; Elizabeth R Sharlow; Peter Wipf; John S Lazo Journal: FASEB J Date: 2018-05-10 Impact factor: 5.191
Authors: Renée Beekman; Marijke Valkhof; Stefan J Erkeland; Erdogan Taskesen; Veronika Rockova; Justine K Peeters; Peter J M Valk; Bob Löwenberg; Ivo P Touw Journal: PLoS One Date: 2011-10-20 Impact factor: 3.240